Purpose of Review The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders. Recent Findings Patients with mood disorders including major depressive disorder (MDD) and bipolar disorder (BD) have higher rates of cannabis use, and CUD compared to the general population. Reasons for this association are not clear, nor are the putative therapeutic effects of cannabis use, or its components delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), in these illnesses. The evidence surrounding treatments for patients with this comorbidity is lacking, with more support for psychotherapeutic treatments compared with pharmacological treatments. Summary Cannabis use may be associated with mood disorders, but more research is needed to increase our understanding of the mechanisms for this association, and to develop more effective treatments for this comorbidity.
Introduction
Cannabis is the most widely used illicit substance in the USA, with~9.5% of adults endorsing use in the past year [1•]. California, the most populous state (~40 million residents), legalized recreational cannabis use on January 1, 2018. Growing acceptance of cannabis use, decreased perception of risk, and debates surrounding individual rights and freedoms in North America are the root of the decision to legalize. The ethical stance at the forefront of legalization is the "harm principle", where adults want the freedom to engage in acts so long as they do not harm others. As of February 2018, nine states and the District of Columbia (DC) have legalized recreational cannabis, and 29 states and DC have legalized cannabis for medicinal purposes. However, there are some negative effects that are critical to consider with widespread legalization, including the impact upon adolescents and people with psychiatric illnesses such as mood disorders. There is evidence demonstrating increased adolescent cannabis use [2] and increased cannabis use disorder (CUD) diagnoses [1•] in states that have legalized recreational cannabis. Furthermore, relatively little is known about the burden of problematic cannabis use on vulnerable populations such as the mentally ill and adolescents.
Cannabis is a plant that is made up of upwards of 113 different chemical components, or cannabinoids [3] . The two cannabinoids that have been most widely studied are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with THC being the main psychoactive component and CBD contributing to many of the therapeutic benefits. Different strains of the cannabis plant have variable concentrations of each of these components, and modern strains have notably high concentrations of THC due to genetic modifications which lead to greater potency [4] . Cannabinoids interact with the G protein-coupled CB1 receptors of the endocannabinoid system (eCB), which in turn influence emotional regulation [5, 6] , reward processing [7] , and various cognitive functions [8] [9] [10] . Additionally, administration of CB1 antagonist, rimonabant, has been found to produce changes in symptoms This article is part of the Topical Collection on Dual Diagnosis of mood and anxiety [11] . Together, these findings provide good evidence that substances targeting endocannabinoid receptors have the ability to modulate mood and also that symptoms of mood disorders are linked to endocannabinoid function.
Mood disorders are primarily comprised of major depressive disorder (MDD) and bipolar disorder (BD). There is evidence to demonstrate increased problematic cannabis use in individuals with these disorders [12] . Thus, this review will focus on identifying the links between cannabis use and mood disorders, as well as identifying gaps in the literature, particularly in treatment approaches for this population. Further research on this topic towards developing better treatment and prevention strategies for this vulnerable population should be a priority.
Methods
Original articles were searched for using PubMed, MEDLINE, and PSYCHINFO. The keywords "(Major Depressive Disorder) or (Depression) or (Bipolar Disorder) or (Mood Disorder)" in combination with "(cannabis) or (marijuana)" were used. The information was extracted independently by two of the authors (AML and ASC).
Major Depressive Disorder
MDD is a devastating illness with a current prevalence of5 % (15% lifetime), and the leading cause of disability globally [13] . MDD is characterized by depressed mood, reduced experience of pleasure, changes in sleep, changes in appetite, loss of energy, feelings of guilt, difficulty concentrating, and suicidality [14] . Due to widespread co-occurrence of both cannabis use and MDD diagnoses, as well as the effect that cannabinoids have been found to have on mood regulation [5, 6] , it is critical to understand whether any reciprocal effect exists between these two phenomena. The main research questions we sought to address in this review are whether cannabis use increased the risk for onset of MDD and whether cannabis use exacerbates symptoms of depression. Table 1 summarizes the studies that examine the association between cannabis use and MDD. Two separate studies independently identified a fourfold risk of developing depression in individuals that use cannabis [15, 19] . One of these studies [15] was based on epidemiological data from 1980 with a 16-year follow-up interview. Several additional crosssectional studies have been conducted that examine the comorbidity, and have found an association between CUD and MDD [18, 22] . However, the same limitations apply across all studies using a cross-sectional design of not being able to determine causation. Fortunately, there have also been research studies on this topic that have employed a longitudinal design. A recent meta-analysis assessed 14 longitudinal studies with population-based data that examined this risk for cannabis users to develop depression, and found a moderate association [23••] . The studies evaluated provided inconsistent results with regard to significance of the association [23••] . However, there was a lack of consistency within the definition and measure of cannabis use, as there have been no validated measures developed to assess this. This meta-analysis grouped heavy users as those fitting the criteria for CUD or weekly users in attempt to create more consistency across the studies, but it is important that future researchers work to create a validated measure of cannabis use across the research discipline [23••] . Finally, a recent twin study has helped to elucidate the temporal relationship of the association, and provided a model for understanding the development of this comorbidity [31] . They found that CUD risk factors lead to MDD symptoms using a model fitting approach [31] .
In terms of our second research question of whether cannabis use worsens symptoms of depression in patients with MDD, the available literature is limited with the exception of one recent study. The study was a longitudinal design using data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), which examined substance use and psychiatric symptoms in the general population at two time points [29••] . Researchers examined whether varying levels of cannabis use at baseline affected clinical outcomes at the follow-up time point in individuals with a diagnosis of MDD [29••] . They found that cannabis use was associated with an increased number of depressive symptoms at follow-up, including anhedonia, changes in body weight, insomnia, hypersomnia, and psychomotor problems [29••] . This study is the first of its kind to examine the effects of cannabis on symptom progression in individuals with MDD. Further studies with this population using well-controlled designs are warranted to remove the confounding factors and more precisely capture this effect. Several longitudinal studies did examine cannabis use and depressive symptoms over time, but used community samples rather than a MDD patient sample [21, 27] . Interestingly, two studies examined the effects of reducing cannabis use on psychiatric symptomology [25•, 30 •]. The first study was a secondary analysis of a randomized control trial (RCT) for motivational interviewing in cannabis-using young female adults, and found that decreasing cannabis use improved depressive symptoms in those with a baseline level of depression [25•] . The second study used a sample of cannabis-dependent patients with schizophrenia who achieved extended cannabis abstinence for a 28-day period, and found a reduction in depressive symptoms with biochemically confirmed abstinence [30•] . Further research is warranted on cannabis use within the MDD diagnostic category to determine an answer to our second research question. 
Bipolar Disorder
BD is characterized by alternating moods, from extreme emotional highs (mania) to extreme emotional lows (depression). It is estimated that 2.6% of adults in the USA are afflicted with symptoms of bipolar disorder in a 12-month period, and that 82.9% of these cases are deemed severe [32] . According to data extracted from the NESARC study, individuals with bipolar disorder have a specific predisposition for increased rates of cannabis use and CUD diagnoses compared to other psychiatric diagnoses [12] . Specifically, individuals with lifetime prevalence of BD have 7.2% past year rate of CUD compared with 1.2% in the general population [33••] . Additionally, when compared with MDD, individuals with BD use cannabis more frequently and in higher quantities [34] . Due to this specific tendency towards problematic cannabis use in patients with BD, it is important to assess the impact this has on outcomes of the disorder. Using the same research questions as before, we reviewed the current literature to determine how cannabis use effects onset and symptom progression of BD. Table 2 . Both studies employed a crosssectional design in adults with a diagnosis of BD, but one study only looked at manic symptom onset [41•] , and the other looked at onset of manic episodes, depressive episodes, and hypomanic episodes [38•] . Both studies indicate a doseresponse relationship between cannabis use and the onset of these symptoms. However, due to the cross-sectional design, causal inferences cannot be made and a longitudinal design of the development of BD in cannabis users would provide better precision and accuracy of measures.
The existing literature suggests moderate evidence that cannabis exacerbates symptoms of bipolar disorder. The study based on the NESARC data demonstrated an association between CUD and a higher frequency of bipolar-related symptoms as well as other substance use comorbidities (alcohol and nicotine) [33••] . The bipolar-related symptoms assessed in this study included manic, hypomanic, and depressive episodes, indicating an overall worse course of illness in individuals with comorbid BD and CUD [33••] . A recent meta-analysis which assessed longitudinal designs found a significant relationship between cannabis use and exacerbation of mania [39] . However, only two studies met criteria for inclusion in the meta-analysis and they were based on community samples [39] . Additionally, the two studies included did not control for psychotic symptoms which may be an important confounding factor when assessing mania in individuals with BD [39] . Interestingly, a recent retrospective analysis found that adults with BD and comorbid CUD performed better on cognitive tasks related to attention, processing speed, and working memory compared to those without CUD, but were more likely to have a psychotic episode [36] . The researchers speculate that this may be due to the higher cognitive and social function required to acquire cannabis [36] . Finally, a secondary analysis of a longitudinal study in adults with BD found that symptom exacerbation of cannabis use on BD dissolved following cannabis cessation [40••] . The researchers separated patients into three groups based on their cannabis use: (i) previous use, (ii) current use, or (iii) never use [40••] . They followed these patients over the course of 2 years and assessed measures of remission, recovery, recurrence, and relapse of symptoms [40••] . Further clinical studies are warranted of cannabis abstinence and its potential to improve outcomes of bipolar disorder.
Pharmacological Treatments
Pharmacological treatments for mood disorders have been well-established. In treating MDD, there is strong evidence supporting the use of antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), dopamine-norepinephrine reuptake inhibitors (DNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs) [42] . Moreover, the first-line treatment for chronic patients with BD is the use of mood stabilizers (e.g., lithium, valproate) [43] , but secondgeneration antipsychotic medications have also been found effective for managing acute symptoms of mania [44] . In contrast, pharmacological treatments for cannabis use have demonstrated inconclusive results based on RCTs, and no medications have been FDA approved for this purpose. Cannabinoid agonists such as dronabinol and nabilone have been explored, but the evidence for these medications has been inconsistent. Three studies found nonsignificant results for improvement on cannabis use measures [45] [46] [47] and two studies found a decrease in withdrawal symptoms following drug administration [48, 49] . N-acetylcysteine may have some potential in reducing craving [50] and improving abstinence rates [51] , but subsequent studies demonstrated nonsignificant results [52] . Gabapentin, baclofen, and nabiximols are additional agents that hold potential for managing cannabis misuse by reducing quantity of use, craving, and withdrawal, respectively [53] [54] [55] . A recent study found that topiramate in combination with psychotherapy reduced rates of cannabis use in adolescents, but was poorly tolerated [56] . All of these drugs have yet to be investigated in individuals with psychiatric comorbidities.
Fortunately, a few recent studies have begun to investigate potential treatments for cannabis use in individuals with comorbid mood disorders. Only two studies utilized a sample with comorbid MDD and CUD to investigate whether antidepressants (fluoxetine and venlafaxine) improve outcomes for both conditions [57•, 58•] . Unfortunately, both studies found no support for the use of these drugs for improving comorbid outcomes including depressive and cannabis-related symptoms [57•, 58•] . One study investigated the effect of lithium on cannabis use outcomes in an open-label trial and found improved abstinence outcomes and decreased symptoms of anxiety and depression [59] . Finally, another open-label trial investigated the effects of the second-generation antipsychotic quetiapine in cannabis-dependent individuals and found a significant decreased in urine THC levels [60] . Patients with cooccurring mood disorder diagnoses were not included in these open-label trials, so further research is warranted on the effects of these drugs on comorbid mood disorders with cannabis use.
Behavioral Treatments
Cognitive behavioral therapy (CBT) is the first-line evidencebased psychotherapeutic treatment for all mood disorders [42, 44] . This psychotherapy is tailored to the individual diagnosis and also has demonstrated some efficacy in the treatment of CUD [61] [62] [63] . The first two studies are based on a large RCT which involved tailored psychotherapy for CUD, including motivational enhancement treatment (MET), CBT, and psychosocial problem-solving training (PPS) [61, 62] . The researchers found that this combined treatment was effective for improving abstinence rates and decreasing cannabis use in both experimental and clinical settings [61, 62, 64] . The other study was an open trial of a group therapy, integrated group therapy (IGT), that incorporated elements of CBT directed to mood and drug use outcomes in patients with BD [62] . IGT lead to better abstinence outcomes for patients with bipolar disorder and substance dependence [62] . Multidimensional Family Therapy (MDFT) has also been explored in an RCT for individuals with CUD [63] . Researchers found that MDFT is equally effective at reducing cannabis use compared to CBT, but that adolescents with comorbid psychiatric disorders such as MDD or BD may benefit more from MDFT [63] .
MET may be useful at invoking initial behavioral change in individuals with a CUD based on the results of two RCTs [25•, 65] . Finally, contingency management (CM) has also been investigated as a method to target cannabis use. Several longitudinal studies have demonstrated that CM is an effective way at promoting cannabis abstinence in patients with mental illness [66] .
Integrated Treatments
There is little existing literature on an integrated treatment approach which combines validated pharmacological with psychotherapeutic treatments on patients with this comorbidity. However, the psychotherapeutic strategies for reducing substance use mentioned previously in combination with the pharmacological agents that have produced favorable results (e.g., gabapentin and N-acetylcysteine) may lead to reductions in cannabis use [67] . Future researchers might consider a combination of psychotherapeutic and pharmacological strategies to reduce mood symptoms, withdrawal symptoms, craving, and improve rates of abstinence.
Conclusions
Given the shifting political and legal landscape surrounding cannabis legalization and the high prevalence of comorbid mood disorders and problematic cannabis use, it is critical that further research be conducted to better understand this population. There are many gaps in the literature on the effects of cannabis on mental illness, and this might be in part due to the classification of cannabis as a Schedule 1 substance by the Drug Enforcement Administration (DEA), and this heavy regulation might have hindered the ability of researchers to obtain and study the substance. Another barrier may be the lack of funding priority that goes towards research focusing on addictions and mental illness, particularly with cannabis due to it being perceived as less harmful compared to other illicit drugs. Research on comorbidities with cannabis has focused to date mainly on schizophrenia due to interest in the cognitive and clinical effects of cannabis [12] . However, given that recreational legalization of cannabis is spreading across the USA and Canada, it is imperative that priority should be given to develop a pre-post legalization surveillance strategy to monitor health outcomes and rates of onset of in people with mood disorders, given their higher population prevalence compared to psychotic disorders [68] . Research on outcomes and potential treatments for vulnerable populations, such as individuals with mood disorders, should be expected and funded by the governmental organizations that are ultimately responsible for public policy changes. According to the currently available research, there is sufficient evidence to suggest an association between cannabis use and the development of depressive symptoms, and some evidence to support exacerbation of MDD symptoms from cannabis use. Much of the literature is based on population-based data, but clinical studies are warranted to more closely examine the progression of depressive symptoms in individuals using cannabis. There are clearly higher rates of cannabis use in individuals with BD, and there is moderate evidence to support an earlier onset of symptoms in problematic cannabis users. There is also moderate evidence that cannabis use exacerbates symptoms in individuals with BD, which is provided by both population-based and clinical research. There are no current pharmacological treatments that have sufficient evidence to warrant recommendation for use in this population, but psychotherapeutic techniques show promise. Particularly CBT, MET, and MDFT have been shown to be efficacious. There is a clear need for more controlled, longitudinal, clinical research on the effects of cannabis use and abstinence on outcomes of mood disorders to better prepare for these potential impacts and minimize potential burdens on health. Moreover, future research may also shed light on treatment approaches that would be beneficial to this population as policy changes continue to take place. 
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